Are you in a crisis? Call or text 988 to speak to a crisis counselor.

Ex-NHLer’s Hopemark Health is Bringing Much-Needed Big Data to Psychedelic Medicine

The world is slowly creeping towards a future where individuals suffering from mental health issues can turn to psychedelic medicine for treatment. Over the last few years, there have been numerous advancements in the space, including positive human trials showing that drugs like psilocybin, MDMA and ketamine are effective in treating a host of mental health disorders.

Activists are using these studies to push for an overhaul of the laws governing psychedelics. Laws outlawing psychedelic drugs have been overturned in cities such as Denver, Oakland and Washington, D.C. Most significantly, Oregon became the first state to decriminalize psilocybin and legalize it for medical purposes.

As this emerging industry matures, there will be a significant need for data showing how effective various psychedelic drugs treat specific disorders. One company has developed a software platform that will assist patients and doctors in keeping track of progress made during psychedelic treatments.

Introducing Hopemark Health

Founded in 2020 by retired NHL veteran Daniel Carcillo, Hopemark Health (CSE: WESA) (OTCQB: WSNAF) is a relatively new player in the psychedelic medicine industry. The company describes itself as an integrated life sciences company and states its mission as:

“We’re on a mission to revolutionize the treatment of neurological health and performance through advanced technology, personalized treatment and psychedelic therapies.”

Read full article here

150 150 leilanifera